<DOC>
	<DOCNO>NCT01516749</DOCNO>
	<brief_summary>This open-label , proof-of-concept research study ass effectiveness anakinra treatment patient hidradenitis suppurativa ( HS ) . The plan intervention provide 6 HS patient anakinra 100mg daily injection administer subcutaneously 8 week . Then , study subject follow 8 week monitor relapse HS .</brief_summary>
	<brief_title>Anakinra Treatment Hydradenitis Suppurativa</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>1 ) Signed informed consent form Confirmed diagnosis hidradenitis suppurativa moderate severe disease activity 1 . Use follow therapy : Etanercept 4 week prior baseline visit ( Day 1 ) Adalimumab 8 week prior baseline visit ( Day 1 ) Infliximab 12 week prior baseline visit ( Day 1 ) Any investigational biologics 8 week prior baseline visit ( Day 1 ) Leflunomide 4 week prior baseline visit ( Day 1 ) â€¢ Thalidomide 4 week prior baseline visit ( Day 1 ) Cyclosporine 4 week prior baseline visit ( Day 1 ) I.V . immunoglobulin ( I.V . Ig ) 8 week prior baseline visit ( Day 1 ) 6Mercaptopurine , azathioprine , cyclophosphamide , chlorambucil 12 week prior baseline visit ( Day 1 ) Colchicine , dapsone , mycophenolate mofetil &amp; systemic antibiotic 3 week prior baseline visit ( Day 1 ) Corticosteroids `` 20mg/day &gt; 0.4 mg/kg , whichever applies , 1 week prior baseline visit ( Day 1 ) 2. history immunocompromise include HIV infection 3. positive Hep B surface antigen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>hidradenitis suppurativa</keyword>
	<keyword>anakinra</keyword>
</DOC>